The EuroNanoMed ERA-Net INITIATIVE: Nano, from research to patient and industry
Nanotechnology applied to health is a strategic priority for Europe because the technologies related to this field have an immense potential to improve public welfare and to enhance economic growth, thus changing the way of life of citizens.
The critical issues to address in order to increase the potential of nanomedicine in Europe are the maturity of the economic players and their capability to move innovation effectively from knowledge to industrial technology and clinical applications.
In this context the EuroNanoMed ERA-Net initiative comprising 24 partners from 18 countries/regions is supported by the European Commission. It was created as a result of the commitment of European member states and regions to support trans-national RTD projects. A key factor for the success of the initiative is the effective coordination of national or regional publicly funded programmes in the field of nanomedicine.
The aim of EuroNanoMed is to foster the competitiveness of European nanomedicine actors through the support of trans-national collaborative and multidisciplinary Research and Technology Development (RTD) projects with participants ranging from academia, clinical/public health communities, and industry (particularly small and medium-sized enterprises).
To fulfil its mission, EuroNanoMed will launch 2 joint transnational Calls for Proposals (in 2009 and 2010) with a total budget of approximately 40-60 M€, corresponding to 10-15% of the sum of the 24 national/regional partners budget specifically dedicated to support Nanomedicine applications.
EuroNanoMed aspires to bridge over the gap between academic research, industries and clinical applications and to shorten the time from the research results to the clinical and/or industrial application for the benefit of the patients.
EuroNanoMed is a major opportunity for European enterprises, research and clinicians communities to take advantage of the flexible coordination of several existing national and regional funding programmes to expand their options for fruitful cross-border partnerships.
Expected outcome:
-
Advance innovation from knowledge to industrial technology and health care applications
-
Open national programmes to support transnational RTD partnerships